Tivic Health Files Patent for Noninvasive Vagus Nerve Stimulation

Bioelectric medicine company Tivic Health has filed its first patent for vagus nerve stimulation with the U.S. Patent Office (USPTO) to expand its intellectual property portfolio into new target areas.
 
The company’s previous patents focused on the trigeminal and sympathetic nerve structures. The new filing addresses a novel approach on non-invasive vagus nerve stimulation (nVNS). The patent includes a novel circuit design to more precisely target the signals carried by the vagus nerve, with a potential to provide superior efficacy to alternative nVNS approaches.
 
The vagus nerve is responsible for regulation of organ function, carrying sensory information, controlling muscles, and influencing the immune system. Vagus nerve stimulation has been proven effective for conditions including treatment-resistant depression, epilepsy, and migraine.
 
“Non-invasive stimulation with precision targeting of the vagus nerve is directly in support of our strategic goals to expand our proprietary footprint in bioelectronic medicine,” Jennifer Ernst, CEO of Tivic told the press. “This patent could advance the field of bioelectronic medicine with a more precise approach to the treatment of cardiovascular, neurological/psychiatric, and systemic inflammatory chronic health conditions without surgery, implants, or pharmaceuticals.”
 
Tivic at this time has five issued U.S. patents, 96 claims. And 20 pending patent in the U.S. and abroad.
 
The company’s ClearUP product, its first commercial offering, is an over-the-counter bioelectronic device that’s FDA approved to treat symptoms of inflammation like sinus pain and congestion.